{"id":"ly2605541","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LY2605541 is a modified human insulin designed to have an extended duration of action, allowing for less frequent dosing compared to standard insulin formulations. It works by activating insulin receptors on target tissues, promoting glucose uptake and utilization while suppressing hepatic glucose production. The structural modifications enable sustained absorption and prolonged pharmacodynamic activity.","oneSentence":"LY2605541 is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose levels in diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:53.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02132637","phase":"PHASE3","title":"A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-05","conditions":"Type 2 Diabetes Mellitus","enrollment":68},{"nctId":"NCT01769404","phase":"PHASE1","title":"A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-02","conditions":"Diabetes Mellitus, Type 1","enrollment":25},{"nctId":"NCT03025009","phase":"PHASE1","title":"A Study of LY3192767 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-03-06","conditions":"Healthy","enrollment":57},{"nctId":"NCT01894568","phase":"PHASE3","title":"A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":388},{"nctId":"NCT01784211","phase":"PHASE1","title":"A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-02","conditions":"Diabetes Mellitus, Type 1","enrollment":76},{"nctId":"NCT01771250","phase":"PHASE1","title":"A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-10","conditions":"Diabetes Mellitus, Type 1","enrollment":15},{"nctId":"NCT01654380","phase":"PHASE1","title":"A Study of LY2605541 Versus Insulin Glargine on Blood Sugar","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Healthy Volunteers, Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT02109029","phase":"PHASE1","title":"A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT01925989","phase":"PHASE1","title":"A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11","conditions":"Type 1 Diabetes Mellitus","enrollment":27},{"nctId":"NCT02152384","phase":"PHASE1","title":"A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-06","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT02197520","phase":"PHASE1","title":"A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-07","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT01995526","phase":"PHASE1","title":"A Study of Insulin Peglispro in Healthy Male Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-12","conditions":"Healthy Volunteers","enrollment":11},{"nctId":"NCT01751399","phase":"PHASE1","title":"A Single Dose Study of LY2605541 in Participants With Liver Impairment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-12","conditions":"Healthy Volunteers, Hepatic Insufficiency, Diabetes Mellitus, Type 2","enrollment":35},{"nctId":"NCT01877265","phase":"PHASE1","title":"A Study of LY2605541 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT01818245","phase":"PHASE1","title":"A Study of LY2605541 in Healthy Participants and in the Elderly","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Healthy Volunteers","enrollment":52},{"nctId":"NCT01027871","phase":"PHASE2","title":"A Study for Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-01","conditions":"Diabetes Mellitus, Type 2","enrollment":289},{"nctId":"NCT01790438","phase":"PHASE3","title":"A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Diabetes Mellitus, Type 2","enrollment":641},{"nctId":"NCT01582451","phase":"PHASE3","title":"A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":466},{"nctId":"NCT01792284","phase":"PHASE3","title":"A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-02","conditions":"Type 1 Diabetes Mellitus","enrollment":212},{"nctId":"NCT01468987","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-12","conditions":"Diabetes Mellitus, Type 2","enrollment":1369},{"nctId":"NCT01481779","phase":"PHASE3","title":"A Study in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-01","conditions":"Diabetes Mellitus, Type 1","enrollment":455},{"nctId":"NCT01454284","phase":"PHASE3","title":"A Study in Participants With Type I Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-01","conditions":"Diabetes Mellitus, Type 1","enrollment":1114},{"nctId":"NCT01049412","phase":"PHASE2","title":"A Study for Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-01","conditions":"Diabetes Mellitus, Type 1","enrollment":138},{"nctId":"NCT01435616","phase":"PHASE3","title":"A Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 2","enrollment":1538},{"nctId":"NCT02106364","phase":"PHASE3","title":"A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2015-02","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01871493","phase":"PHASE1","title":"A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Healthy Volunteers","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABASIA"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"CRYING"},{"count":1,"reaction":"DEPRESSION"},{"count":1,"reaction":"DRUG-INDUCED LIVER INJURY"},{"count":1,"reaction":"FALL"},{"count":1,"reaction":"FEMUR FRACTURE"},{"count":1,"reaction":"GASTRIC BYPASS"},{"count":1,"reaction":"HAEMOGLOBIN DECREASED"},{"count":1,"reaction":"HIP FRACTURE"}],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Insulin Peglispro","Insulin peglispro"],"phase":"phase_3","status":"active","brandName":"LY2605541","genericName":"LY2605541","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"LY2605541 is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose levels in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}